Clinical presentation and proteomic signature of patients with TANGO2 mutations.
| Authors | |
| Abstract | Transport And Golgi Organization protein 2 (TANGO2) deficiency has recently been identified as a rare metabolic disorder with a distinct clinical and biochemical phenotype of recurrent metabolic crises, hypoglycemia, lactic acidosis, rhabdomyolysis, arrhythmias, and encephalopathy with cognitive decline. We report nine subjects from seven independent families, and we studied muscle histology, respiratory chain enzyme activities in skeletal muscle and proteomic signature of fibroblasts. All nine subjects carried autosomal recessive TANGO2 mutations. Two carried the reported deletion of exons 3 to 9, one homozygous, one heterozygous with a 22q11.21 microdeletion inherited in trans. The other subjects carried three novel homozygous (c.262C>T/p.Arg88*; c.220A>C/p.Thr74Pro; c.380+1G>A), and two further novel heterozygous (c.6_9del/p.Phe6del); c.11-13delTCT/p.Phe5del mutations. Immunoblot analysis detected a significant decrease of TANGO2 protein. Muscle histology showed mild variation of fiber diameter, no ragged-red/cytochrome c oxidase-negative fibers and a defect of multiple respiratory chain enzymes and coenzyme Q (CoQ ) in two cases, suggesting a possible secondary defect of oxidative phosphorylation. Proteomic analysis in fibroblasts revealed significant changes in components of the mitochondrial fatty acid oxidation, plasma membrane, endoplasmic reticulum-Golgi network and secretory pathways. Clinical presentation of TANGO2 mutations is homogeneous and clinically recognizable. The hemizygous mutations in two patients suggest that some mutations leading to allele loss are difficult to detect. A combined defect of the respiratory chain enzymes and CoQ with altered levels of several membrane proteins provides molecular insights into the underlying pathophysiology and may guide rational new therapeutic interventions. |
| Year of Publication | 2020
|
| Journal | J Inherit Metab Dis
|
| Volume | 43
|
| Issue | 2
|
| Pages | 297-308
|
| Date Published | 2020 Mar
|
| ISSN | 1573-2665
|
| DOI | 10.1002/jimd.12156
|
| PubMed ID | 31339582
|
| PubMed Central ID | PMC7078914
|
| Links | |
| Grant list | CP09/00011 / Instituto de Salud Carlos III
NIHR-HCS-D12-03-04 / National Institute for Health Research (NIHR) doctoral fellowship
FP7/2007-2013 / FEuropean Union Seventh Framework Programme
345/C/2014rm Care (CA) / Instituto de la Marató de TV3
2017SGR1206 / CERCA Programme/ Generalitat de Catalunya, the Hesperia Foundation, the Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia
2014: SGR 393 / Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR)
21644 / Association Française contre les Myopathies (FR)
MR/N027302/1 / Newton Fund
PI17-01286 / Instituto de Salud Carlos III
PI14/00581 / Instituto de Salud Carlos III
G0800674 / Mitochondrial Disease Patient Cohort (UK)
PI16/01048 / Instituto de Salud Carlos III
109915/Z/15/Z / Wellcome Investigator
201064/Z/16/Z / Wellcome Trust Pathfinder Scheme
309548 / ERC_ / European Research Council / International
203105/Z/16/Z / Wellcome Centre for Mitochondrial Research
MR/N025431/1 / MRC_ / Medical Research Council / United Kingdom
PI17/00109 / Instituto de Salud Carlos III
PI16/00579 / Instituto de Salud Carlos III
WT_ / Wellcome Trust / United Kingdom
|